Cramer's Morning Take: Bristol Myers & Eli Lilly 11/25/24
Squawk on the Street
00:00
Investment Insights: Bristol-Myers and Its Game-Changing Schizophrenia Drug
This chapter explores Bristol-Myers' new schizophrenia drug and its potential impact on investment portfolios. It also examines upcoming patent cliffs and their projected effects on earnings by 2028, placing the discussion within the larger context of pharmaceutical investments.
Transcript
Play full episode
